CD274 and inflammatory breast carcinoma: By studying genetic variants and the tumor immune microenvironment in IBC patients, our study suggests that IBC patients with HRR mutations could have benefited from the combination of PARP-inhibitor and PD-L1/PD-1 blocking therapies.